OmniAb to Participate in Upcoming Investor Conferences in May

Rhea-AI Summary

OmniAb, Inc. (NASDAQ: OABI) announced its participation in five investor conferences throughout May 2023. Highlights include:

• H.C. Wainwright BioConnect Investor Conference on May 2, 2023, featuring a fireside chat at 9:30 a.m. ET and one-on-one meetings in New York City.
• E.F. Hutton Global Conference on May 10-11, 2023, with one-on-one meetings on May 11 at The Plaza Hotel, New York City.
• Benchmark 3rd Annual Virtual Healthcare House Call on May 23, 2023, hosting virtual one-on-one meetings.
• B. Riley Securities 23rd Annual Institutional Investor Conference on May 24-25, 2023, with meetings on May 24 in Beverly Hills.
• Craig-Hallum 20th Annual Institutional Investor Conference on May 31, 2023, at The Depot Renaissance Minneapolis Hotel.

OmniAb's platform supports pharmaceutical partners in discovering next-generation therapeutics via diverse antibody repertoires.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five upcoming investor conferences in May.

• H.C. Wainwright BioConnect Investor Conference at NASDAQ, May 2, 2023 at Nasdaq World Headquarters, New York City. Management will be participating in a fireside chat on Tuesday, May 2^nd at 9:30 a.m. Eastern time and will be hosting one-on-one meetings with investors.

• Inaugural E.F. Hutton Global Conference, May 10-11, 2023 at The Plaza Hotel, New York City. Management will be hosting one-on-one meetings with investors on May 11.

• Benchmark 3^rd Annual Virtual Healthcare House Call 1x1 Investor Conference, May 23, 2023. Management will be hosting virtual one-on-one meetings with investors.

• B. Riley Securities 23^rd Annual Institutional Investor Conference, May 24-25, 2023 at The Beverly Hilton, Beverly Hills. Management will be hosting one-on-one meetings with investors on May 24.

• Craig-Hallum 20^th Annual Institutional Investor Conference, May 31, 2023 at The Depot Renaissance Minneapolis Hotel, Minneapolis. Management will be hosting one-on-one meetings with investors.

About OmniAb^®

OmniAb’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat^®, OmniChicken^® and OmniMouse^® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic^® (transgenic rat) and OmniClic^® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur™ features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities in emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others. The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

For more information, please visit www.omniab.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005012/en/

OmniAb, Inc.

Neha Singh

investors@OmniAb.com

Twitter @OmniAbTech

(510) 768-7760

LHA Investor Relations

Yvonne Briggs

ybriggs@lhai.com

(310) 691-7100

Source: OmniAb, Inc.

FAQ

What conferences will OmniAb (OABI) attend in May 2023?

OmniAb will participate in five investor conferences in May 2023, including the H.C. Wainwright BioConnect Investor Conference on May 2, the E.F. Hutton Global Conference on May 10-11, the Benchmark Virtual Healthcare House Call on May 23, the B. Riley Securities Conference on May 24-25, and the Craig-Hallum Conference on May 31.

When is the H.C. Wainwright BioConnect Investor Conference for OmniAb?

The H.C. Wainwright BioConnect Investor Conference is scheduled for May 2, 2023, at 9:30 a.m. Eastern Time in New York City.

Where will OmniAb hold one-on-one meetings during the E.F. Hutton Global Conference?

OmniAb will host one-on-one meetings on May 11, 2023, during the E.F. Hutton Global Conference at The Plaza Hotel in New York City.

What is the focus of OmniAb's discovery platform?

OmniAb's discovery platform focuses on providing pharmaceutical partners access to diverse antibody repertoires and high-throughput screening technologies for developing next-generation therapeutics.

What types of technology does OmniAb utilize for antibody discovery?

OmniAb uses various technologies including Biological Intelligence, transgenic animals for antibody generation, and advanced computational antigen design for antibody discovery.